Drug Combination Details
| General Information of the Combination (ID: C48090) | |||||
|---|---|---|---|---|---|
| Name | Celastrol NP Info | + | Afatinib Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Mitochondrial Ca2+ overload | ||||
| Induction | ROS accumulation | |||||
| In-vitro Model | NCI-H23 | CVCL_1547 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H292 | CVCL_0455 | Lung mucoepidermoid carcinoma | Homo sapiens | |||
| In-vivo Model | A volume of 100 ul H23 cell suspension (1 * 108 cells/ml in normal saline) was subcutaneously injected into the right flanks of mouse (male BALB/c nude mice of 4-5 weeks old). | |||||
| Experimental
Result(s) |
Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Celastrol acts synergistically with afatinib to suppress non-small cell lung cancer cell proliferation by inducing paraptosis. J Cell Physiol. 2021 Jun;236(6):4538-4554. | |||
